Therapeutics News and Research

RSS

Findings may help in development of new anti-inflammatory compounds

Virginia Commonwealth University researchers studying the enzyme that triggers inflammation have found that it may be a target for a new class of anti-inflammatory drugs to treat arthritis, asthma, multiple sclerosis, lung and colon cancers and Alzheimer's disease.

2 Dec 2005

Why we put weight back on

You've successfully dropped those extra pounds only to discover that they creep back on again. Columbia University researchers may have now worked out why.

2 Dec 2005

Spear Therapeutics raise $8.5 Million to fund cancer drug development

Cancer Research Technology (CRT), Bloomsbury Bioseed Fund (BBSF), De Montfort University (DMU) and the Gray Cancer Institute announce today that U.S. venture capital firm Advent International has invested $8.5 million in Spear Therapeutics Ltd.

28 Nov 2005

Fullerenes can help fend off damage to normal tissue from radiation

Using transparent zebrafish embryos, researchers at Jefferson Medical College have shown that a microscopic nanoparticle can help fend off damage to normal tissue from radiation.

28 Nov 2005

Human umbilical cord blood cells may widen treatment window for stroke

An experimental treatment that spares disability from acute stroke may be delivered much later than the current three-hour treatment standard – a potential advance needed to benefit more stroke victims.

13 Nov 2005

Introgen's INGN 241 combined with Celebrex kills breast cancer cells

Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.

8 Nov 2005

Error found in standard guidelines on fetal varicella syndrome

The UK’s Drug and Therapeutics Bulletin (DTB), published by Which?, has identified an important error in standard guidelines on fetal varicella syndrome. This finding has major implications worldwide for advice given to women with chickenpox in late pregnancy.

7 Nov 2005

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

3 Nov 2005

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) in Paris have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

1 Nov 2005

EphA2 represents a promising treatment target for glioblastoma multiforme

Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.

1 Nov 2005

Functional diffusion map to help predict brain tumor outcomes

A special type of MRI scan that measures the movement of water molecules through the brain can help doctors determine halfway through treatment whether it will successfully shrink the tumor or a patient's cancer will continue to grow, a new study shows.

1 Nov 2005

Northwestern University move closer to new therapies for neurodegenerative disease

French neurologist Jean-Martin Charcot first described amyotrophic lateral sclerosis (ALS) in 1869, but, nearly 140 years later, little is known about the cause of the devastating neurodegenerative disease, and there is no cure.

27 Oct 2005

Australian researchers determine structure of JAK2 kinase, huge implications for development of new cancer drugs

Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs.

25 Oct 2005

Two competing drug-eluting stents work equally well

After completing the most comprehensive U.S.-based study of its kind, Dr. Charles Simonton reported that the performance of two competing coronary stents was "virtually identical" in head-to-head comparisons.

25 Oct 2005

DOS47 scientific paper published in the Journal of Experimental Therapeutics and Oncology

Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."

25 Oct 2005

Researchers learn to rapidly rebuild immunity in immune-suppressed cancer patients

Patients with multiple myeloma suffer from a malignant proliferation of plasma cells in their bone marrow. The standard treatment for this form of cancer is high-dose chemotherapy and transplantation of one's own blood-producing adult stem cells; however, this aggressive treatment wipes out the mature immune-system cells of patients – leaving them vulnerable to infection.

20 Oct 2005

New tool that may prove to be invaluable for investigating the long-term mutagenic effects of chemotherapy and radiation

Scientists have developed a new tool that may prove to be invaluable for investigating the long-term mutagenic effects of chemotherapy and radiation, therapies that are widely used for the treatment of cancer.

17 Oct 2005

dnaJP1 - novel drug for the treatment of rheumatoid arthritis

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

16 Oct 2005

Curry spice appears to shut down a protein active in the spread of breast cancer

Curcumin, the main ingredient of turmeric and the compound that gives curry its mustard-yellow color, inhibits metastasis to the lungs of mice with breast cancer, report researchers at The University of Texas M. D. Anderson Cancer Center

16 Oct 2005

E-cadherin, that cellular touch so important in cancer

E-cadherin is a molecule involved in adhesion between epithelial cells that also seems to have a protective role in cancer, since its loss is associated with tumour progression and metastases formation in a series of different cancers.

16 Oct 2005